GLP-1 — Articles & guides | Uplevel Bio

Compound

Everything we've written on GLP-1 — 19 articles covering the mechanism, the evidence, comparisons, and practical considerations.

19 articles

Metabolic healthFood noise — the obsession with eating you can't think your way out ofIt starts before breakfast is over. You're still eating and already thinking about lunch — what you'll have, whether that's too much, whether you should have eaten what you just ate, what you'll do to compensate. By mid-morning there's a quiet negotiation running in the background: if you skip the afternoon snack, you can have a real dinner. If you have the good lunch, maybe just a small dinner. You're not even hungry. You're just... in it. The loop is running whether you want it to or not.8 min read Origins and discoveryThe GLP-1 discovery deeper history — Holst, Mojsov, and the science before the drugIn 1982, Jens Juul Holst was working in a basement laboratory at the University of Copenhagen, trying to understand what the gut did with glucose. Not what happened in the bloodstream afterward. Not what the pancreas produced. What the gut itself was doing — the biochemical signaling that happened in the intestinal wall in the seconds and minutes after food arrived. It was methodical, unglamorous work: isolating intestinal tissue from pigs and dogs, running extracts through high-performance liquid chromatography, measuring immunoreactive peptide fractions that no one had fully characterized. One of those fractions kept showing up in a way that suggested it was derived from the glucagon gene but wasn't glucagon. It behaved differently. It appeared in the intestine rather than the pancreas. And it seemed, in preliminary experiments, to do something interesting to insulin secretion.11 min read Origins and discoveryThe history of GLP-1 research — from Habener and Drucker to OzempicIn 1987, a paper appeared in the Proceedings of the National Academy of Sciences describing the structure of proglucagon — the precursor protein that the body cleaves into multiple peptides depending on which tissue is doing the cleaving. Joel Habener's laboratory at Massachusetts General Hospital had worked out the sequence and identified, buried inside it, two peptides that looked like distant relatives of glucagon. They called them glucagon-like peptide-1 and glucagon-like peptide-2. The paper was read by people who study pancreatic hormones. It was not a cultural event. Nobody wrote about it in a newspaper. The molecule's future wasn't legible yet from what Habener's group knew at that point.9 min read Women's hormonal healthGLP-1s in perimenopause — when nothing else is workingYou are eating the way you ate at thirty-five. You're training four days a week, sometimes five. You sleep reasonably well, you don't drink much, you track your food on and off and it's not dramatic. And the weight is still going in the wrong direction, or it isn't moving at all, or it's moving to your abdomen and waist in a way it never did before and no amount of core work touches it. You've been told it's stress. You've been told it's perimenopause and to just wait it out. You've been told your labs are normal. And you're standing in a body that feels like it's operating on entirely different rules than the one you've lived in for the last two decades.4 min read Metabolic healthWhy the scale stops moving on a GLP-1 — and what to do about the plateauThe first three months were real. The number moved every week — sometimes every few days. Clothes fit differently. People asked if you'd done something different. You had more energy in the afternoon. And then, somewhere around month four or five, the scale stopped. You're eating the same way. You haven't quit the medication. The number just sits there, stubborn and unmoved, and the quiet voice that says maybe this is it, maybe this is as far as it goes, gets a little louder every week.4 min read Metabolic healthWeight regain after stopping a GLP-1 — what's biological, what's behavioral, what to doYou lost thirty pounds over nine months. You ate less without fighting yourself about it, which was new. The background noise of food — the constant low-level negotiation between wanting something and deciding not to have it — went quiet in a way it never had before. And then, for whatever reason — cost, the medication becoming unavailable, your provider recommending a break, your own decision — you stopped. The quiet lasted maybe three weeks. And then the noise came back.3 min read Origins and discoveryThe longevity movement — from caloric restriction in mice to Ozempic on TikTokIn 1993, a researcher named Cynthia Kenyon walked into a genetics seminar at UC San Francisco and announced that she had doubled the lifespan of a roundworm. Not extended it modestly. Doubled it. The mutation was in a single gene, daf-2, which encodes a receptor for an insulin-like growth factor. The worms lived twice as long, moved like younger worms, and showed no obvious tradeoffs. The audience, by several accounts, went quiet in a way that academic audiences rarely do. The implication was too large to hold comfortably: that aging itself might be a regulated process. That it might be intervened upon.10 min read Immune modulationThe microbiome and peptides — where the gut bacteria meet the signaling moleculesThe patient had been through three rounds of antibiotics in two years — a sinus infection, then a skin infection, then a dental procedure that required prophylaxis. Each time the antibiotics worked. Each time, afterward, something shifted in the gut. The digestion that had always been unremarkable became unpredictable. The immune system that had always been quiet developed a new habit of overreacting. The energy, mood, and sleep quality that nobody associates with gut health began varying in ways that felt random but weren't. Nobody mentioned that the gut would need to be rebuilt.12 min read Origins and discoveryHow peptides became a drug category — from insulin to GLP-1, one hundred years of peptide pharmacologyIt is January 11, 1922, and a fourteen-year-old boy named Leonard Thompson is lying in a Toronto hospital bed. He has had type 1 diabetes for two years. He weighs sixty-five pounds. His blood sugar is five hundred milligrams per deciliter. He has been on a severe starvation diet — the only management available — which is buying him weeks. Frederick Banting and Charles Best inject him with a partially purified extract from canine pancreatic tissue. He goes into anaphylactic shock. The extract is crude, contaminated, and the dose is poorly characterized. They stop. They spend the next twelve days refining the preparation with a biochemist named James Collip. On January 23, they inject Thompson again. Within twenty-four hours his blood sugar drops to normal. The boy who was starving in a Toronto hospital lives for another thirteen years before dying, not from diabetes, of pneumonia. In those thirteen years he is the first human being to survive a disease that had been uniformly fatal in juveniles since antiquity.12 min read Origins and discoveryThe decades arc of peptide research — what's changed and what's recurredIn 1921, Frederick Banting was a twenty-nine-year-old Canadian surgeon with a research idea that his department chairman at the University of Toronto considered unpromising. The idea was that insulin — the pancreatic secretion that had been hypothesized for decades to regulate blood sugar — could be isolated and used to treat diabetic patients who would otherwise die. Banting had read a paper about the pancreatic islet cells and had a method in mind for isolating their secretion without contaminating it with the destructive enzymes produced by surrounding tissue. His chairman, J.J.R. Macleod, gave him a laboratory, a summer, a young biochemist named Charles Best, and a collection of experimental dogs. By the end of that summer, the extract worked in dogs. By January 1922, Leonard Thompson — a fourteen-year-old diabetic patient near death in Toronto General Hospital — received the first injection in a human being. By the end of the century, the compound that Banting and Best partially purified in that summer laboratory had been re-engineered through recombinant DNA technology, was being produced by bacteria carrying a human gene, and was keeping approximately nine million Americans alive.11 min read Women's hormonal healthPeptides for perimenopause — across the four shifts that happen at onceYou wake up at 3 a.m. soaked in sweat, heart thumping, and by the time you kick the covers off you're cold. An hour later you're awake again, this time for no reason you can name — just alert, mind moving, the familiar tired-but-wired feeling you've been carrying for months. Your cycle has been irregular for about a year. Some months it's fine. Other months you skip entirely, or it arrives weeks early and harder than it used to. You mentioned the sleep to your doctor and she said your labs were normal. Estrogen looked fine, she said. Maybe stress.10 min read Women's hormonal healthPeptides and pregnancy preparation — what to discontinue, what may help preconceptionYou've been building a wellness protocol for a while — maybe a GLP-1 agonist, maybe a peptide or two, maybe a stack of supplements that took months to refine. And then comes the conversation where you decide you want to try to conceive. And suddenly the question is not what to add. The question is what to stop, when to stop it, and what the three to six months before trying actually requires of you biologically.10 min read Metabolic healthRetatrutide in plain English — the triple agonist that may eclipse tirzepatideYou've been on tirzepatide for six months. The first three were dramatic — ten pounds the first month, then eight, then seven. The nausea became manageable. The appetite that had organized your life for decades became something you could ignore for hours at a time. And then, somewhere around month four or five, the number on the scale stopped moving. Not reversed. Not stalled terribly. Just plateaued at a point that isn't where you were hoping to be. Your prescribing provider says this is expected. The dose is at its maximum. Your body has found a new equilibrium.8 min read Metabolic healthRetatrutide trial data, in plain English — what the Phase II results showedYou've probably seen the number: 24 percent. It circulates in metabolic health communities the way promising trial results always do — stripped of context, amplified by enthusiasm, attached to before-and-after speculation that arrives well ahead of the actual drug. Twenty-four percent body weight loss. If that number is real, it's the largest effect size the obesity pharmacology space has ever produced in a clinical trial. The question worth asking — the one that gets asked less often than the number gets cited — is what exactly the trial showed, how it was designed, what the caveats are, and why Phase II results and Phase III results are not the same thing.8 min read Metabolic healthSemaglutide vs. tirzepatide: how to actually decide between themYou've done enough research to know that both medications are weekly injectables, that both work through GLP-1, that both have produced results in trials that made headlines. And now you're at the actual decision point — which one, and why — and the information available online tends to either oversimplify it ("tirzepatide is stronger, tirzepatide wins") or hedge so thoroughly it says nothing useful. The honest answer is that it depends on specific things about you, and those things can be named.6 min read Metabolic healthWhy you can't quit the thing you meant to quit — what biology contributesYou made the decision months ago. You were going to drink less — or stop. Cut the sugar. Stop vaping. Spend less time on the thing that was eating your evenings. You meant it. You started. You held it for a few days, maybe a week, and then something happened — a stressful afternoon, a social situation, a moment of restlessness that required an answer — and you were back in the pattern you'd decided to leave. You tried again. You've tried several times by now. Each attempt begins with genuine intent and ends in a version of the same place. The explanation offered by most of your life — by culture, by most advice — is that you lack willpower. That the difference between people who quit and people who don't is discipline, character, sustained commitment to the thing they said they wanted.8 min read Metabolic healthThe energy crash after meals you didn't have beforeAn hour after lunch — sometimes forty-five minutes — a wall comes up. Not tiredness exactly, though it presents as tiredness: the eyelids that get heavy, the mind that loses its sharpness, the body that would like, very much, to be horizontal. It's the quality of energy that was there before lunch that is simply gone, and a certain glueyness has replaced it. It's not every meal. It's most meals with meaningful carbohydrates — the sandwich, the pasta, the grain bowl that seemed like a reasonable lunch. And it's not because you're sleeping badly or because you're working fourteen-hour days, though you might be doing both of those things. It's happening on the reasonable days too, at reasonable lunches, at the unremarkable midweek moments when you have no particular reason to be running low. Your doctor's response, when you mention it: everyone gets a bit sleepy after lunch, that's normal, maybe cut back on the coffee so the afternoon isn't a crash from caffeine. Which doesn't address what you're actually describing at all.8 min read Metabolic healthFoggy after meals — when food shouldn't make you slowerAfter lunch you lose an hour. Not to sleep — you're at your desk, your eyes are open, you're technically present — but something has left the building. Decisions feel harder. Words come slower. You read the same paragraph twice and absorb roughly nothing. This isn't fatigue exactly, or not only fatigue. It's specifically cognitive. The screen looks fine. Your body is sitting still. But your brain has moved to a different timezone, and the distance is most obvious in the thirty to ninety minutes after you eat.8 min read Metabolic healthThe mood that came with the weight — when body composition starts affecting how you feelIt's not that you're depressed. You've thought about that word and it doesn't quite fit. You're functional. You're getting through the days, meeting the obligations, showing up. But something has flattened. The spark that used to be there — the one that made you want to start things, that made a good conversation feel genuinely good — is turned down. You feel more muted. Less yourself. And it tracked, you've noticed, with the weight that came on over the last few years. Not sudden weight, not dramatic weight, just the slow accumulation that happens when a lot of other things shift at once. And the question you keep circling is whether the mood caused the weight — the low motivation, the less movement, the eating that felt comforting when you felt flat — or whether the weight caused the mood. Or both.8 min read

← All articles